Michael Wagner studied chemistry at the University of Mainz, Germany and Cornell University, USA. In 2002 he received his Ph.D. in Organic & Bioorganic Chemistry from the University of Mainz and joined Sanofi right afterwards as principal scientist. Since then, in positions with increasing responsibility, he has built a successful track record of delivering high quality candidates for preclinical & clinical development comprising different therapeutic modalities (small molecules, peptides, proteins & polymers) in a variety of indications, including cardiovascular disease, pain, osteoarthritis and diabetes but also for imaging purposes. In 2010, Michael accepted a director position within the Diabetes Therapeutic Unit as Head of Medicinal Chemistry. Since 2011, he has been establishing a professional peptide drug discovery group in Frankfurt and became department head “Peptides & Insulins” in 2016. Since October 2017, Michael Wagner is leading the department “Synthetic Medicinal Modalities” within Integrated Drug Discovery, which takes care of small molecule medicinal chemistry as well as peptide drug discovery supporting therapeutic areas such as diabetes, immunology, rare disease and oncology. Beyond classical drug discovery approaches Michael’s interests lie in the delivery of macromolecules, specifically peptides.
For sustained delivery of peptides Michael’s department has been researching polymer based prodrug systems, encapsulation technologies as well as fusion to biopolymers, such as albumin or the FC portion of IgGs. Recent activities focus on the oral delivery of biomacromolecules (peptides & proteins). Michael’s scientific contributions resulted in more than 15 preclinical candidates, from which most have undergone clinical testing. Michael is a co-inventor of more than 40 patents (issued or filed) and co-author of more than 25 research publications.